✓ The histocompatibility requirements for successful frozen nerve allografts were studied in 46 dogs. Major canine histocompatibility (DLA) differences appeared to be of vital importance for nerve regeneration and function, as judged by histological and electromyographic performance 7 to 9 months after grafting. Minor histocompatibility differences did not appear to lead to rejection of the frozen nerve allografts. Graft irradiation did not improve the acceptability of frozen DLA-mismatched grafts. The effect of DLA matching was much more pronounced in allografts 7 cm long than in allografts 4 cm long. The results indicate the need for a bank of frozen human histocompatible (HLA) nerve allografts, and a study of the effect of partial or complete HLA matching on their survival.
Journal Article Failure of Clinical Remission after Transsphenoidal Removal of a Microadenoma in a Patient with Cushing's Disease: Multiple Hyperplastic and Adenomatous Cell Nests in Surrounding Pituitary Tissuetitle Get access STEVEN W.J. LAMBERTS, STEVEN W.J. LAMBERTS 1Departments of Internal Medicine (III) and Clinical Endocrinology the Hague, the Netherlands; Institute of Pathology, Department of Neuropathology the Hague, the Netherlands; Department of Neurosurgery the Hague, the Netherlands; Department of Othorhinology the Hague, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar STANISLAW Z. STEFANKO, STANISLAW Z. STEFANKO 1Departments of Internal Medicine (III) and Clinical Endocrinology the Hague, the Netherlands; Institute of Pathology, Department of Neuropathology the Hague, the Netherlands; Department of Neurosurgery the Hague, the Netherlands; Department of Othorhinology the Hague, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar SAM A. DE LANGE, SAM A. DE LANGE 1Departments of Internal Medicine (III) and Clinical Endocrinology the Hague, the Netherlands; Institute of Pathology, Department of Neuropathology the Hague, the Netherlands; Department of Neurosurgery the Hague, the Netherlands; Department of Othorhinology the Hague, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar HUIB FERMIN, HUIB FERMIN 1Departments of Internal Medicine (III) and Clinical Endocrinology the Hague, the Netherlands; Institute of Pathology, Department of Neuropathology the Hague, the Netherlands; Department of Neurosurgery the Hague, the Netherlands; Department of Othorhinology the Hague, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar JAN-CAREL M. VAN DER VIJVER, JAN-CAREL M. VAN DER VIJVER 5Erasmus University Rotterdam, and the Department of Medicine, Leyenburg Hospital the Hague, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar ROB F. A. WEBER, ROB F. A. WEBER 1Departments of Internal Medicine (III) and Clinical Endocrinology the Hague, the Netherlands; Institute of Pathology, Department of Neuropathology the Hague, the Netherlands; Department of Neurosurgery the Hague, the Netherlands; Department of Othorhinology the Hague, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar FRANK H. DE JONG FRANK H. DE JONG 1Departments of Internal Medicine (III) and Clinical Endocrinology the Hague, the Netherlands; Institute of Pathology, Department of Neuropathology the Hague, the Netherlands; Department of Neurosurgery the Hague, the Netherlands; Department of Othorhinology the Hague, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar The Journal of Clinical Endocrinology & Metabolism, Volume 50, Issue 4, 1 April 1980, Pages 793–795, https://doi.org/10.1210/jcem-50-4-793 Published: 01 April 1980 Article history Received: 12 September 1979 Published: 01 April 1980
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Paraneoplastic disorders may be defined as diseases which are due to tumours elsewhere in the body but not caused by a local metastasis or tumour infiltrations. Other terms used in literature are paracarcinomatous syndrome and meta-carcinomatous syndrome.
Abstract. Bromocriptine treatment results in clinical improvement and inhibition of plasma GH levels in only part of the acromegalic patients. The possible role of the simultaneous presence of Prl and GH in GH-secreting pituitary adenomas was investigated with regard to the inhibitory action of bromocriptine on GH secretion and the paradoxical increase of GH release in reaction to TRH. Surgically obtained pituitary tumour tissue from 35 consecutive acromegalic patients was studied immunohistochemically. In 21 patients no Prl was present in the tumour tissue. These patients had normal plasma Prl levels. In the other 14 patients Prl was present in the tumour tissue. Hyperprolactinaemia was found in 10 of these 14 patients. Plasma GH levels from 2 till 10 h after the administration of 2.5 mg bromocriptine measured before operation were significantly more suppressed in the patients with mixed GH/Prl-containing than in those with pure GH-containing pituitary adenomas, being 38 ± 4% and 65 ± 4% of basal values, respectively ( P < 0.01). The response of GH to TRH, however, did not differ significantly between the two groups. Conclusions: 1. In about 70% of patients with 'mixed' GH/Prl containing adenomas, hyperprolactinaemia is present. 2. The simultaneous presence of Prl and GH in a GH-secreting pituitary tumour increases the sensitivity of GH secretion to bromocriptine. 3. The plasma Prl level is of value to predict which patients with acromegaly are likely to respond to bromocriptine with an inhibition of GH secretion.
